DOI: 10.1097/01.IDT.0000352540.93338.84

,  

Issn Print: 1936-9255

Publication Date: 2009/07/01


Print

Clinical Pharmacogenetics in Psychiatry: Psychopharm Review

    loading  Checking for direct PDF access through Ovid

Excerpt

Online quiz instructions: To take the quiz online, go to http://cme.LWWnewsletters.com, and enter your username and password. Your username will be the letters LWW (case sensitive) followed by the 12-digit account number on your mailing label. You may also find your account number on the paper answer form mailed with your issue. Your password will be 1234; this password may not be changed. Follow the instructions on the site. You may print your official certificate immediately. Please note: Lippincott CME Institute, Inc., will not mail certificates to online participants. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. Select the best answer and use a blue or black pen to completely fill in the corresponding box on the enclosed answer form. Please indicate any name and address changes directly on the answer form. If your name and address do not appear on the answer form, please print that information in the blank space at the top left of the page. Make a photocopy of the completed answer form for your own files and send the original answer form to Lippincott Williams & Wilkins, Office of Continuing Education Department, P.O. Box 1543, Hagerstown, MD 21741–9914 by June 30, 2010. For more information, call (800) 787–8981. The CME credits are included in the subscription price.
1. In addition to carbamazepine, the FDA has issued advisories to warn of the possibility of Stevens-Johnson syndrome in HLA-B*1502-positive patients receiving
A. valproic acid
B. phenytoin
C. lamotrigine
D. oxcarbazepine
E. topiramate
2. In patients receiving carbamazepine, HLA-B*1502 has been linked with
A. anticonvulsant hypersensitivity syndrome
B. toxic epidermal necrolysis
C. diffuse maculopapular rash
D. all the above
3. All of the following patient groups taking carbamazepine should be tested for the HLA-B*1502 allele, except
A. Japanese
B. Asians who have tolerated carbamazepine for more than 3 months
C. Taiwanese
D. Indian-Americans
E. All of the above populations warrant testing
4. Ultra-rapid metabolizers of CYP2D6 substrates are found in high frequency in
A. Malaysians
B. Moroccans
C. Mexicans
D. African-Americans
5. Which one of the following statements regarding CYP2D6 phenotypes is false?
A. Ultra-rapid metabolizers have multiple copies of the wild type CYP2D6 allele.
B. Poor metabolizers are more likely than extensive metabolizers to experience adequate analgesic effects when treated with codeine or oxycodone.
C. Extensive metabolizers are transformed into poor metabolizers when given paroxetine.
D. Ultra-rapid metabolizers may have a higher risk of nonresponse to conventional doses of aripiprazole.
E. CATIE trial showed no difference in treatment outcomes or side effects among different metabolizer phenotypes.
    loading  Loading Related Articles